Download PDF
Aktuelle Rheumatologie 2018; 43(04): 289-296
DOI: 10.1055/a-0649-4933
Übersichtsarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Leben mit Rheuma: Rehabilitation und adjuvante Therapien

Living with Rheumatism: Rehabilitation and Adjuvant Therapies
Marina Clasen
,
Andreas Schwarting
1   Schwerpunkt für Rheumatologie und klinische Immunologie, Universitätsmedizin Mainz I. Medizinische Klinik und Poliklinik, Mainz, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
23 August 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Entwicklung neuer zielgerichteter medikamentöser Therapien hat zu einer deutlichen Verbesserung der Behandlung der akuten Entzündungsaktivität geführt. Die größere Herausforderung stellt im Alltag oftmals jedoch der Umgang mit bereits eingetretenen Behinderungen und Schmerzen dar. Hierfür gibt es zahlreiche adjuvante Möglichkeiten, deren Stellenwert im Beitrag erörtert wird.

Abstract

Novel targeted therapies have successfully reduced the acute inflammatory activity of rheumatic diseases. However, existing functional incapacities and disabilities are often more challenging in daily routine practice. To treat these, there are numerous adjuvant therapeutic approaches, whose significance is discussed in the following article.

Schlüsselwörter

Rehabilitation - Phytopharmaka - adjuvante Therapie

Key words

rehabilitation - adjuvant therapy - phytopharmaceuticals
 

  • Literatur

  • 1 Mau W, Beyer W, Ehlebracht-König I. et al. Treat to Participation. Zeitschrift für Rheumatologie 2015; 74: 553-557
    CrossrefPubMedGoogle Scholar
  • 2 Alvarez-Hernandez E, Cesar Casasola-Vargas J, Lino-Perez L. et al. Complementary and alternative medicine in patients attending a rheumatology department for the first time. Analysis of 800 patients. Reumatol Clin 2006; 2: 183-189
    CrossrefPubMedGoogle Scholar
  • 3 Schneider M, LM Abholz HH et al. Management der frühen rheumatoiden Arthritis – Interdisziplinäre S3-Leitlinie. 2011; Klinische Leitlinie im Auftrag der Deutschen Gesellschaft für Rheumatologie. Available from: https://dgrh.de/dam/jcr:b5dea1ff-4643-46b2-bff0-be-9d7593075e/7_komplementaere_verfahren_ra.pdf
    PubMed
  • 4 Al-Yasiry ARM, Kiczorowska B. Frankincense–therapeutic properties. Postepy Hig Med Dosw (online) 2016; 70: 380-391
    CrossrefPubMedGoogle Scholar
  • 5 Ammon HPT. Boswelliasäuren (Inhaltsstoffe des Weihrauchs)als wirksame Prinzipien zur Behandlung chronisch entzündlicher Erkrankungen*. Wiener Medizinische Wochenschrift 2002; 152: 373-378
    CrossrefPubMedGoogle Scholar
  • 6 Ammon HPT. Boswellic Acids and Their Role in Chronic Inflammatory Diseases, in Anti-inflammatory Nutraceuticals and Chronic Diseases. Gupta SC, Prasad S, Aggarwal BB. Editors. Springer International Publishing: Cham. 2016: 291-327
    Google Scholar
  • 7 Yousefi B, Jadidi-Niaragh F, Azizi G. et al. The role of leukotrienes in immunopathogenesis of rheumatoid arthritis. Modern Rheumatology 2013; 1-14
    PubMedGoogle Scholar
  • 8 Ernst E. Frankincense: Systematic review. BMJ: British Medical Journal 2008; 337.
    PubMed
  • 9 Butterweck V. Mechanism of Action of St John’s Wort in Depression. CNS Drugs 2003; 17: 539-562
    CrossrefPubMedGoogle Scholar
  • 10 Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Frontiers in Pharmacology 2013; 4: 177
    PubMedGoogle Scholar
  • 11 Schmidt M, Butterweck V. The mechanisms of action of St. John’s wort: an update. Wiener Medizinische Wochenschrift 2015; 165: 229-235
    CrossrefPubMedGoogle Scholar
  • 12 Galeotti N. Hypericum perforatum (St John's wort) beyond depression: A therapeutic perspective for pain conditions. Journal of Ethnopharmacology 2017; 200: 136-146
    CrossrefPubMedGoogle Scholar
  • 13 Brendler T, Gruenwald J, Ulbricht C. et al. Devil’s Claw (Harpagophytum procumbens DC). Journal of Herbal Pharmacotherapy 2006; 6: 89-126
    PubMedGoogle Scholar
  • 14 Sticher O, Heilmann J, Zündorf I. Hänsel/ Sticher Pharmakognosie Phytopharmazie. 2015: Wissenschaftliche
    PubMed
  • 15 Grant L, McBean DE. Fyfe L. et al. A review of the biological and potential therapeutic actions of Harpagophytum procumbens. Phytotherapy Research 2007; 21: 199-209
    CrossrefPubMedGoogle Scholar
  • 16 Haseeb A, Ansari MY, Haqqi TM. Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes. Journal of Orthopaedic Research 2017; 35: 311-320
    CrossrefPubMedGoogle Scholar
  • 17 Fiebich BL, Muñoz E, Rose T. et al. Molecular Targets of the Antiinflammatory Harpagophytum procumbens (Devil's claw): Inhibition of TNFα and COX-2 Gene Expression by Preventing Activation of AP-1. Phytotherapy Research 2012; 26: 806-811
    CrossrefPubMedGoogle Scholar
  • 18 Warnock M, McBean D, Suter A. et al. Effectiveness and safety of Devil's Claw tablets in patients with general rheumatic disorders. Phytotherapy Research 2007; 21: 1228-1233
    CrossrefPubMedGoogle Scholar
  • 19 Chantre P, Cappelaere A, Leblan D. et al. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine 2000; 7: 177-183
    CrossrefPubMedGoogle Scholar
  • 20 Frerick H, Biller A, Schmidt U. A treatment schedule for coxarthrosis: A double-blind study with Devil's claw Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle. 2001; 5: 34-41
    PubMedGoogle Scholar
  • 21 Schmidt TJ, Willuhn G, Steigel A. et al. Sesquiterpene Lactones and Inositol Esters from Arnica angustifolia1,*. Planta Med 1995; 61: 544-550
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Merfort I. Arnika: Neue Erkenntnisse zum Wirkungsmechanismus einer traditionellen Heilpflanze. Complementary Medicine Research 2003; 10 (Suppl. 01) 45-48
    CrossrefPubMedGoogle Scholar
  • 23 Dragos D, Gilca M, Gaman L. et al. Phytomedicine in Joint Disorders. Nutrients 2017; 9: 70
    CrossrefPubMedGoogle Scholar
  • 24 Nahrstedt A, Schmidt M, Jäggi R. et al. Willow bark extract: The contribution of polyphenols to the overall effect. Wiener Medizinische Wochenschrift 2007; 157: 348-351
    CrossrefPubMedGoogle Scholar
  • 25 Wegener T. Zur Studienlage von Weidenrindenextrakten. Vol. 30. 2009
    PubMed
  • 26 Biegert C, Wagner I, Ludtke R. et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials. J Rheumatol 2004; 31: 2121-2130
    PubMedGoogle Scholar
  • 27 Products, C.o.H.M. Community Herbal Monograph on Salix, cortex. 2017; Available from: http://www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/herbal/medicines/herbal_med_000072.jsp&mid = WC0b01ac058001fa1d#
    PubMed
  • 28 Vlachojannis JE, Cameron M, Chrubasik S. A systematic review on the effectiveness of willow bark for musculoskeletal pain. Phytother Res 2009; 23: 897-900
    CrossrefPubMedGoogle Scholar
  • 29 Cheung JM, Scarsbrook D, Klinkhoff AV. Characterization of Patients with Arthritis Referred for Gold Therapy in the Era of Biologics. The Journal of Rheumatology 2012; 39: 716-719
    CrossrefPubMedGoogle Scholar
  • 30 Wassenberg S. Parenterale Goldtherapie bei rheumatoider Arthritis – pro. Dtsch med Wochenschr 2011; 136: 1676-1676
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Svensson Å, Möller H, Björkner B. et al. Rheumatoid arthritis, gold therapy, contact allergy and blood cytokines. BMC Dermatology 2002; 2: 2-2
    CrossrefPubMedGoogle Scholar
  • 32 Bendix G, Bjelle A. A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 1996; 55: 169-176
    CrossrefPubMedGoogle Scholar
  • 33 Smolen J, Landewé R, Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases 2017; 0: 1-18
    PubMedGoogle Scholar